Dividend vs. Cash? Take the Cash

Large pharmaceutical companies sharing their cash flow with investors through dividends makes a lot of sense. Honestly, there isn't much reason to own Eli Lilly (NYSE: LLY  ) , GlaxoSmithKline (NYSE: GSK  ) , and AstraZeneca (NYSE: AZN  ) except for their oversized dividends.

But smaller specialty pharma issuing dividends? I really don't get it.

Earlier this year Questcor Pharmaceuticals (NASDAQ: QCOR  ) initiated a quarterly dividend that it's handing out a little early. And this week Spectrum Pharmaceuticals (NASDAQ: SPPI  ) said it's issuing a $0.15-per-share special dividend.

Really, guys? You can't find any better use for the cash?

Granted, Spectrum's dividend is only a one-time cost of $8.9 million and the board gave management an open invitation to repurchase $100 million worth of its stock. But Spectrum has only used $12 million of it, so it's not as if management has been super stoked to return cash to shareholders.

And for good reason.

Much like the generic drug business, the specialty pharma business has the opportunity to improve profits by increasing margins. Buying more drugs produces economies of scale and reduces risk because the specialty pharma is less reliant on a single drug.

I liked Spectrum's recent acquisition of Allos Therapeutics for those exact reasons. The purchase added Folotyn, which will be prescribed by hematologist-oncologists, the same doctors who prescribe Spectrum's Zevalin. Spectrum has been dependent on Fusilev sales, which have skyrocketed over the last year or so but have the potential to come crashing down if generic-drug makers get their act together and fix manufacturing issues of a related generic.

A token gift of 1.3% of the share price doesn't seem all that useful to investors. They'd be much better off if Spectrum kept the money and used it to buy additional drugs, increasing its operating margins in the process.

While Spectrum's special dividend has fueled debate among investors, there are few stocks more contentious than Questcor. Its premium priced drug, Acthar, is growing at a torrid pace -- and minting money in the process. However, recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.


Read/Post Comments (3) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 12, 2012, at 8:17 PM, EVplusEV wrote:

    QCOR was trying to stop the shorts with its dividend announcement.

  • Report this Comment On December 12, 2012, at 8:34 PM, luzzi wrote:

    That's the best part! These guys know what their doing. What don't you get? It's the best of both worlds. With SPPI it's not "Dividend vs Cash?" It's "Dividend & Cash!"

  • Report this Comment On December 13, 2012, at 1:00 AM, vireoman wrote:

    Exactly! QCOR and SPPI are both trying to shake the short-sellers. At the same time, they are making a statement to investors that they are flush with cash and have every reason to believe that they will be generating piles of cash in the future. Smart moves, if you ask me, and I'm an investor in both.

Add your comment.

DocumentId: 2151458, ~/Articles/ArticleHandler.aspx, 4/20/2014 3:31:18 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement